Stoke Therapeutics Director Resigns; Alexander Cumbo Appointed

What Happened
Stoke Therapeutics announced that Class III director Edward M. Kaye, M.D., resigned effective September 23, 2026; the resignation was not due to any disagreement with the company. On September 23, 2026 the Board appointed Alexander (Bo) Cumbo to fill the vacancy as a Class III director, with a term expiring at the 2028 Annual Meeting.

Key Details

• Dr. Kaye’s resignation effective September 23, 2026; not the result of any disagreement with the company.
• Alexander (Bo) Cumbo appointed effective September 23, 2026 and will serve until the 2028 Annual Meeting.
• Cumbo was determined by the Board to be independent under SEC and Nasdaq rules.
• Director compensation: $45,000 annual cash retainer.
• Equity grant: initial option to purchase 39,674 shares (ASC 718 fair value ≈ $724,000); vests in 12 substantially equal quarterly installments.
• Cumbo entered Stoke’s standard director indemnity agreement.

Why It Matters
Board composition affects corporate oversight and governance. The appointment of an independent director and the outlined compensation (cash retainer and equity grant) are routine governance actions that could modestly affect stock-based dilution over time. Investors should note the change in Board membership and the timing of the new director’s term (through the 2028 Annual Meeting) for any proxy or governance-related considerations.